Betta Pharmaceuticals Co., Ltd.

Other

Citrix Systems, Inc.

Beta Pharma, Inc.

Beijing Betta Pharmaceuticals Co., Ltd

Fujian Haixi Pharmaceuticals, Inc.

Betta Pharmacueticals Co., Ltd.

Kang, Xinshan

Wei Long

Yinxiang Wang

Shaojing Hu

Yunyan Hu

Fenlai Tan

Fei Wang

Lieming Ding

Yanping Wang

Cunbo Ma

Hong Cao

Xinshan Kang

Xiaoyan Shen

Wei He

Lei Xu

Yong Liu

Don Zhang

Bin Han

Yongyu Chen

Xiangyong Liu

Guojian Xie

Jinlong Bai

Liang Bao

Charles Davis

Haima Ai

Xiangdong Zhao

Liufeng Zhou

Zhiguo Xu

Zongquan Li

Jianxi Zhang

Haima Al

Techniques are disclosed for content storage in a way that facilitates consistent and concurrent read/write processing of stored documents. An example methodology implementing the techniques includes segmenting the contents of a document into a plurality of content segments and storing the plurality of content segments within a data structure, the data structure including storage blocks having storage portions and buffer portions. The storage of the plurality of content segments includes storage of content segments within a storage portions of the storage blocks of the data structure. The method also includes receiving at least one change to the content and utilizing a buffer portion of at least one storage block to store the at least one change to the content.

Document storage and management

Described embodiments provide systems and methods for resource scaling. A computing device may include a data processor. The data processor may receive, from a distributed database service (DDS), usage data on resource request-units from a plurality of services that use resources provided by the DDS. The computing device may include a transform agent. The transform agent may transform at least a subset of the N sets of data, into at least three transformed datasets each corresponding to a different frequency range. The computing device may include a predictor. The predictor may provide a predicted value of request-units according to the at least three transformed datasets. The predictor may request the DDS to provide the resources up to a number of request-units at a given time instance according to the predicted value.

Resource scaling for distributed database services

The compound of Formula I, the crystalline form thereof, and methods of preparing and using them are provided. 

Crystalline form of fused pyridine derivative's maleate and uses thereof

Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) and ALK kinase activity are disclosed. More specifically, the invention provides pyrimidines which inhibit, regulate and/or modulate kinase receptor, particularly in selectively modulation of various EGFR mutant activity and ALK kinase activity have been disclosed. Pharmaceutical compositions comprising the pyrimidine derivative, and methods of treatment for diseases associated with protein kinase enzymatic activity, particularly EGFR or ALK kinase activity including non-small cell lung cancer comprising administration of the pyrimidine derivative are disclosed.

Protein tyrosine kinase modulators and methods of use

Disclosed is Icotinib phosphate (i.e., the compound of Formula (I)) and polymorph forms thereof, and methods of preparing and using them. 

Polymorphic forms of icotinib phosphate and uses thereof

The present invention relates to the polymorphic forms of the compound of Formula I, preparation thereof and pharmaceutical compositions, and use of a polymorph above in the treatment of a disease, a disorder or a condition, or in the manufacturing of a medicament for the treatment of a disease, a disorder or a condition. 

Polymorphic forms of icotinib and uses thereof

Provided are Icotinib maleate (the compound of Formula I) and polymorph forms thereof, and methods of preparing and using them. 

Polymorphic forms of icotinib maleate and uses thereof

The present invention relates to novel analogs of glucagon like peptide and compositions that are useful for up-regulating insulin expression in mammals and for treating diabetes. In particular, these peptide derivatives have a peptide mimic linker and provides long duration of action for the treatment of diabetes and other insulinotropic peptide related diseases, gastrointestinal function and activities associated with glucagon levels.

Glucagon like peptide analogs, composition, and method of use

The compound of Formula (I), pharmaceutically acceptable salts thereof, solvates thereof, chelates thereof, non-covalent complexes thereof or produgs of compounds mentioned above or the mixture of any form above mentioned are provided. The use of the compounds in manufacturing a medicament for the treatment and/or prevention of diabetes, obesity and related disorders. 

Compound for increasing kinase active and application thereof

The invention relates to 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, its therapeutic usage for treatment of diseases mediated by EGFR kinase and its combinatory therapeutic usage together with other therapeutic agents. The invention also provides synthetic methods for preparation of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, and the relevant synthetic intermediates for synthesis of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride.

Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof

This invention relates to certain novel fused quinazoline derivatives (Formula I) as c-Met inhibitors which is shown as formula I, their synthesis and their use for treating a c-Met mediated disorder. More particularly, this invention is directed to fused heterocyclic derivatives useful inhibitors of c-Met, methods for producing such compounds and methods for treating as c-Met mediated disorder 

Substituted fused heterocycles as c-Met tyrosine kinase inhibitors

The polymorphic forms of the compound of Formula I, the preparation thereof including the preparation of the intermediates, the pharmaceutical compositions thereof and the uses of a polymorph above in the manufacture of medicaments for treating a disease, a disorder or a condition are disclosed. 

Stable polymorphic forms of compound as hypoxia mimetics, and uses thereof

The present invention relates to the polymorphic forms of the compound of Formula (I), preparation thereof including the preparation of intermediates and pharmaceutical compositions, and use of a polymorph above in the treatment of a disease, a disorder or a condition, or in the manufacturing of a medicament for the treatment of a disease, a disorder or a condition. 

Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof

The present invention relates to the technical field of medicine, and specifically provides methods for preparing Icotinib, Icotinib hydrochloride, and intermediates thereof. These methods avoid the use of phosphorus oxychloride, thereby greatly reducing the emission of pollutants, which is of major benefits to the economy and environment.

Growing community of inventors

Beijing, China

Wei Long